Ocrelizumab initiation in patients with MS

Volume: 7, Issue: 4, Pages: e719 - e719
Published: Apr 9, 2020
Abstract
Objective To provide first real-world experience on patients with MS treated with the B cell–depleting antibody ocrelizumab. Methods We retrospectively collected data of patients who had received at least 1 treatment cycle (2 infusions) of ocrelizumab at 3 large neurology centers. Patients' characteristics including premedication, clinical disease course, and documented side effects were analyzed. Results We could identify 210 patients (125...
Paper Details
Title
Ocrelizumab initiation in patients with MS
Published Date
Apr 9, 2020
Volume
7
Issue
4
Pages
e719 - e719
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.